As on Wednesday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) got off with the flyer as it spiked 8.07% to $7.77, before settling in for the price of $7.19 at the close. Taking a more long-term approach, FDMT posted a 52-week range of $2.23-$12.34.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -9.89%. Meanwhile, its Annual Earning per share during the time was -9.89%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -9.35%. This publicly-traded company’s shares outstanding now amounts to $57.14 million, simultaneously with a float of $52.01 million. The organization now has a market capitalization sitting at $443.94 million. At the time of writing, stock’s 50-day Moving Average stood at $10.08, while the 200-day Moving Average is $6.50.
4D Molecular Therapeutics Inc (FDMT) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. 4D Molecular Therapeutics Inc’s current insider ownership accounts for 8.97%, in contrast to 65.82% institutional ownership. According to the most recent insider trade that took place on Dec 20 ’25, this organization’s VP, Finance and Controller sold 389 shares at the rate of 8.68, making the entire transaction reach 3,377 in total value, affecting insider ownership by 46,218. Preceding that transaction, on Dec 16 ’25, Company’s Chief Legal Officer sold 1,635 for 10.90, making the whole transaction’s value amount to 17,822. This particular insider is now the holder of 3,594 in total.
4D Molecular Therapeutics Inc (FDMT) Earnings and Revenue Records
4D Molecular Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -9.35% and is forecasted to reach -3.48 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -5.65% through the next 5 years, which can be compared against the -9.89% growth it accomplished over the previous five years trading on the market.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Let’s observe the current performance indicators for 4D Molecular Therapeutics Inc (FDMT). It’s Quick Ratio in the last reported quarter now stands at 8.42. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3699.49.
In the same vein, FDMT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.94, a figure that is expected to reach -0.53 in the next quarter, and analysts are predicting that it will be -3.48 at the market close of one year from today.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Through scrutinizing the latest numbers posted by the [4D Molecular Therapeutics Inc, FDMT], it can be observed that its last 5-days Average volume of 0.82 million was lower the volume of 0.83 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 33.52% While, its Average True Range was 38.34.
Raw Stochastic average of 4D Molecular Therapeutics Inc (FDMT) in the period of the previous 100 days is set at 28.26%, which indicates a major rise in contrast to 16.70% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.69 that was lower than 0.70 volatility it exhibited in the past 100-days period.
